| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-10-27 | Pfizer (USA - NY) Pain Therapeutics (USA - TX) | REMOXY™ (oxycodone) | moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time | termination |
CNS diseases | Termination of the agreement |
| 2014-10-27 | Epizyme (USA - MA) | resignation |
Resignation | |||
| 2014-10-27 | Galapagos (Belgium) Calchan (UK) | pre-clinical candidate | osteoarthritis pain | R&D |
Inflammatory diseases - Rheumatic diseases - CNS diseases | R&D agreement |
| 2014-10-27 | CTI BioPharma - previously known as Cell Therapeutics (USA - WA) Vernalis (UK) Chroma Therapeutics (UK) | tosedostat | acute myeloid leukemia | licensing |
Cancer - Oncology | Licensing agreement |
| 2014-10-27 | Karyopharm Therapeutics (USA - MD) | Cancer - Oncology - Rare diseases | Establishment of a new subsidiary in the EU | |||
| 2014-10-24 | Eckert & Ziegler (Germany) undisclosed USA based biotech company | undisclosed brand-new radiotherapy product | pancreatic cancer | manufacturing production |
Cancer - Oncology | Production agreement |
| 2014-10-23 | Covidien (Ireland) the American Lung Association (USA - IL) | lung cancer | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2014-10-23 | BiogenIdec (USA - MA) | nomination | Neurodegenerative diseases | Nomination | ||
| 2014-10-23 | Curetech (Israel) Medivation (USA - CA) | pidilizumab (CT-011) | hematological malignancies and solid tumors | licensing |
Cancer - Oncology | Exercise of an option agreement |
| 2014-10-23 | Raptor Pharmaceuticals (USA - CA) | resignation |
Resignation | |||
| 2014-10-23 | Raptor Pharmaceutical (USA - CA) | chief commercial officer, vice-president | nomination | Nomination | ||
| 2014-10-23 | Cardio3 BioSciences (Belgium) | chief medical officer | nomination | Cardiovascular diseases | Nomination | |
| 2014-10-22 | Bavarian Nordic (Denmark) National Institute of Allergy and Infectious Diseases (NIAID) (USA) J&J (USA - NJ) | Ebola vaccine | Ebola fever | collaboration |
Infectious diseases | Collaboration agreement |
| 2014-10-22 | Enigma Diagnostics (UK) Beijing Leadman Biochemistry (China) | joint-venture |
Infectious diseases - Diagnostic | Collaboration agreement | ||
| 2014-10-22 | Bavarian Nordic (Denmark) Crucell, a J&J company (USA - NJ) | MVA-BN® Ebola Vaccine | Ebola fever | licensing supply |
Infectious diseases | Licensing agreement |
| 2014-10-22 | Ipsen (France) Lexicon Pharmaceuticals (USA - TX) | telotristat etiprate | carcinoid syndrome | licensing
|
Cancer - Oncology - Rare diseases | Licensing agreement |
| 2014-10-22 | Atyr Pharma (USA - CA) | vice-president, research | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2014-10-22 | Bavarian Nordic (Denmark) Crucell, a J&J company (USA - NJ) | MVA-BN® | collaboration |
Infectious diseases | Collaboration agreement | |
| 2014-10-21 | Inovio Pharmaceuticals (USA - PA) , MedImmune (USA - global biologics arm of AstraZeneca (UK), University of Pennsylvania (USA - PA) | DNA-based monoclonal antibodies | influenza virus infection, Pseudomonas aeruginosa virus infection, Staphylococcus aureus virus infection | development |
Infectious diseases | Development agreement |
| 2014-10-21 | Immunotech Laboratories (USA - CA) Uldic Investment (Zimbawe) | Immune Therapeutic Vaccine-1 (ITV-1) | Ebola fever | collaboration |
Infectious diseases | Collaboration agreement |
